BLU-525

BLU-525 is a **small molecule, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor** developed by Blueprint Medicines for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC)[4][7]. It features a distinct chemical structure compared to earlier candidates (like BLU-701), offers improved kinome selectivity, differentiated metabolism, wild-type EGFR selectivity, strong coverage of EGFR mutations (including exon 19 deletions and L858R), and central nervous system (CNS) penetration[4][5][10]. The drug is designed to address resistance mutations such as EGFR C797S that emerge during treatment with third-generation EGFR inhibitors like osimertinib[4][7][8][10]. As of May 2023, the US FDA had accepted the Investigational New Drug (IND) application for BLU-525 for NSCLC, and it remains in early clinical development[7][8][4]. Blueprint Medicines is the primary developer, with licensing agreements in Greater China with Zai Lab[2].

Other names

BLU 525BLU525BLU-525